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1. Introduction 
Nicotinamide phosphoribosyltransferase (NAMPT, EC 2.4.2.12) catalyzes the condensation 
of nicotinamide with 5-phosphoribosyl-1-pyrophosphate (PRPP) to yield nicotinamide 
mononucleotide (NMN), a rate limiting enzyme in a mammalian salvage pathway of 
nicotinamide adenine dinucleotide (NAD) synthesis. Human NAMPT consists of 491 amino 
acids with a molecular weight of 52 kDa (Samal et al., 1994). NAMPT was initially named 
pre-B-cell colony-enhancing factor (PBEF) for its growth factor like function on promoting 
pre-B-cell colony formation in the presence of stem cell factor plus interleukin 7 (Samal et 
al., 1994). Martin et al. (2001) found that the gene encoding the bacterial Haemophilus ducreyi 
nicotinamide phosphoribosyltransferase (nadV) had a significant homology to the 
mammalian PBEF gene. Since then, Rongvaux et al.(2002), Revollo et al. (2004) and others 
(van der Veer et al., 2005) have characterized the enzymological features of mammalian 
NAMPT. In 2005, NAMPT/PBEF was named visfatin, a “new visceral fat-derived 
hormone”, which is an adipocyte-derived adipokine that induces insulin mimetic effects 
(Fukuhara et al., 2005). To avoid the confusion, the name NAMPT will be used throughout 
this chapter since NAMPT was approved as the official name of this gene by the Human 
Genome Organization Gene Nomenclature Committee.  
Because of NAMPT’s pleiotropic functions in a variety of physiological processes, the 
dysregulation of NAMPT activity has been implicated in the pathogenesis of a number of 
human diseases or conditions such as acute lung injury, aging, atherosclerosis, cancer, 
diabetes, obesity related disease, rheumatoid arthritis and sepsis (Borradaile & Pickering, 
2009; Galli et al., 2010; Moschen et al., 2010). Therefore, targeted inhibition of NAMPT has 
become an attractive therapeutic strategy for these related diseases. Inhibition of NAMPT 
has been actively pursued as a potential new therapeutic modality to treat patients with 
cancer in clinical trials, to inhibit rheumatoid arthritis and to attenuate acute lung injury. 
The list of 'inhibition of NAMPT based therapy' is expanding rapidly. The initially tested 
inhibitors include FK866 (now called APO866, a small chemical molecule), antisense oligo, 
siRNA or shRNA and antibody. 
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This chapter will review the latest findings on NAMPT inhibitors in human clinical trials, 
animal studies and cell cultural experiments from published literature and our research 
findings. The first part will briefly cover the current understanding of NAMPT physiology. 
The second part will describe the pathological roles of NAMPT in various human diseases. 
The third and major component of this chapter will focus on the development, action 
mechanisms, and applications of various inhibitors of NAMPT. The biochemical and 
molecular characterization of various inhibitors to NAMPT looms large in this part. 
Perspective remarks at the end will provide some food for thought for future directions on 
the development of new and improved NAMPT inhibitors. 
2. Physiology of NAMPT 
This section deals with the three major functions of NAMPT: growth factor, cytokine and 
nicotinamide phosphoribosyltransferase. Accumulating evidence suggests that NAMPT can 
function as a growth factor or a cytokine though the underlying molecular mechanisms 
remain to be established. It is beyond dispute that NAMPT can function as a nicotinamide 
phosphoribosyltransferase. 
2.1 Growth factor 
Growth factor generally refers to a naturally occurring protein capable of stimulating cellular 
growth, proliferation and differentiation. Growth factors are important for regulating a variety 
of cellular processes. Several studies indicate that NAMPT may function as a growth factor. 
Samal et al. (1994) first found that NAMPT can enhance significantly the number of pre-B-cell 
colonies derived from normal human or mouse bone marrow by at least 70% in the presence of 
both IL-7 and stem cell factor. Thus, the authors first named this protein as pre-B-cell colony 
enhancing factor. Van der Veer et al. (2005) reported that NAMPT can promote vascular 
smooth muscle cell maturation. Human smooth muscle cells transduced with the NAMPT 
gene had enhanced survival. Fukuhara and co-workers (2005) proposed NAMPT as a visfatin, 
an adipokine produced by visceral fat that can engage and activate the insulin receptor (IR). 
Although this original publication was retracted (Fukuhara et al., 2007) because of questions 
regarding the reproducibility of the NAMPT/IR interaction from different preparations of 
recombinant NAMPT protein, Xie et al. found that NAMPT exerts an insulin-like activity as a 
growth factor for osteoblasts. They noticed that the effects of NAMPT, such as glucose uptake, 
proliferation, and type I collagen enhancement in cultured human osteoblast-like cells, bore a 
close resemblance to those of insulin and were inhibited by hydroxy-2-
naphthalenylmethylphosphonic acid tris-acetoxymethyl ester (HNMPA-[AM]3), a specific 
inhibitor of IR tyrosine kinase activity (Xie et al., 2007).  
2.2 Cytokine 
Cytokine is sometimes used interchangeably among scientists with the term growth factor. 
The term cytokine encompasses a large and diverse family of polypeptide regulators that 
are produced widely throughout the body by cells of diverse embryological origin. Their 
actions may be grouped as autocrine, paracrine and endocrine. NAMPT may be added to 
the list of cytokines. The first NAMPT cDNA was screened out using a degenerate 
oligonucleotide probe designed on the basis of the similarity in the coding sequences of five 
different cytokines (GM-CSF, IL-2, IL-1ǃ, IL-6 and IL-13), at the signal peptidase processing 
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site, though the DNA or protein sequence of NAMPT bears no homology to other known 
cytokines (Samal et al., 1994). Ognjanovic and colleagues reported that recombinant 
human NAMPT (rhNAMPT) treatment of WISH cells and fetal membrane explants 
significantly increased IL-6 and IL-8 gene expression (Ognjanovic et al., 2001; Ognjanovic 
& Bryant-Greenwood, 2002). We also found that an overexpression of NAMPT 
significantly augmented IL-8 secretion and mRNA expression in A549 cells, a human 
pulmonary carcinoma type II epithelial cell line, and in human pulmonary artery 
endothelial cells (Li, H. et al., 2008; Liu, P. et al., 2009). It also significantly augmented IL-
1ǃ-mediated cell permeability. The opposite results were obtained with the knockdown of 
NAMPT expression. NAMPT expression also affected the expression of two other 
inflammatory cytokines (IL-16 and CCR3) (Li, H. et al., 2008; Liu, P. et al., 2009). Hong et 
al. (2008) demonstrated that rhNAMPT functions as a direct rat neutrophil chemotactic 
factor in in vitro studies. They also detected a marked increase in bronchoalveolar lavage 
leukocytes after the intratracheal injection of rhNAMPT into C57BL/6J mice. Thus, 
NAMPT behaves like a chemokine. 
2.3 Nicotinamide phosphoribosyltransferase 
The clue that PBEF could be a nicotinamide phosphoribosyl transferase was first obtained 
by the work of Martin et al. (2001). They found that the sequence of nadV gene is 
homologous to that of human NAMPT, suggesting that mammalian PBEF may also function 
as a NAMPT. Rongvaux et al. (2002) verified that similarly to its microbial counterpart, 
mouse PBEF is a NAMPT, catalyzing the condensation of nicotinamide with PRPP to yield 
NMN. Revollo et al. (2004) demonstrated further that NAMPT catalyzes a rate-limiting step 
in a salvage pathway of the mammalian NAD biosynthesis. Van der Veer et al. (2005) 
established that enhanced NAMPT activity is linked directly to the lengthening of the 
cellular lifespan of both human smooth muscle cells and fibroblasts. Recent work by Revollo 
et al. (2007) revealed that NAMPT regulates insulin secretion in beta cells as a systemic NAD 
biosynthetic enzyme. Because the salvage pathway of NAD synthesis has a faster rate and is 
more efficient than that of de novo NAD synthesis, it is conceivable that NAMPT plays an 
important role in a variety of physiological processes via the regulation of NAD synthesis.  
3. Pathophysiology of NAMPT 
This section presents potential roles of NAMPT in human diseases. The dysregulation of 
the NAMPT gene has been implicated in the susceptibility and pathogenesis of a number 
of human diseases and conditions because of its pleiotropic physiological functions. There 
is strong supporting evidence that both tissue and circulating NAMPT levels change in 
acute respiratory distress syndrome, aging, atherosclerosis, cancer, diabetes, rheumatoid 
arthritis, and sepsis.  
3.1 Acute respiratory distress syndrome (ARDS) 
ARDS is the severe form of acute lung injury (ALI). ALI is characterized by pulmonary 
inflammation, non-cardiogenic edema, and severe systemic hypoxemia (Ware & Matthay, 
2000; Wheeler & Bernard, 2007). One of the earliest manifestations of ALI is a diffuse, 
intense inflammatory process and damage to both endothelial and epithelial cell barriers, 
resulting in marked extravasation of vascular fluid into the alveolar airspace (Matthay et al., 
www.intechopen.com
 
Chemical Biology 44
2003). A number of inflammatory cytokines including tumor necrosis factor-alpha (TNFǂ) 
and interleukin 8 (IL-8) can induce or aggravate the inflammation of endothelial and 
epithelial cells, leading to these barrier dysfunctions (Frank et al., 2006) and pathogenesis of 
ALI. The mortality and morbidity of ALI/ARDS remain high since the etiology and 
molecular pathogenesis are still not understood completely. 
To identify novel candidate ALI genes, our lab employed a high-throughput functional 
genomics approach and found that NAMPT was a highly expressed gene in canine, murine 
and human ALI (Ye et al., 2005a). These results suggest that NAMPT may be a potential 
biomarker in ALI. Analysis of single nucleotide polymorphisms (SNPs) in the NAMPT gene 
proximal promoter region indicated that a GC haplotype had a higher risk (nearly 8 fold) of 
ALI, while a TT haplotype had a lower risk of ALI (Ye et al., 2005a). Our findings were 
confirmed and extended by Bajwa et al. (2007). These results support that NAMPT is a 
genetic marker for ALI. To investigate further the role and molecular mechanism underlying 
NAMPT in the pathogenesis of ALI, we showed that heterozygous NAMPT (+/-) mice were 
protected significantly from severe ventilator associated lung injury (VALI) (Hong et al., 
2008). We also found that the NAMPT-specific siRNA would attenuate thrombin-induced 
decreases in human lung endothelial cell barrier function, increased cytoskeletal 
rearrangement, and secretion of the proinflammatory cytokine IL-8 (Ye et al., 2005b). 
Overexpression of NAMPT significantly augmented IL-8 secretion and IL-8 mRNA 
expression in A549 cells and human pulmonary artery endothelial cells (HPAEC), 
respectively. NAMPT expression also affected the expression of two other inflammatory 
cytokines (IL-16 and CCR3) (Li, H. et al., 2008; Liu, P. et al., 2009). These results reveal that 
NAMPT overexpression may adversely affect pulmonary cell barrier function, the 
deregulation of which is the well-recognized feature in the pathogenesis of ALI. 
3.2 Aging 
Aging is the accumulation of changes in an organism over time. Several evidences suggest 
that NAMPT may be an important regulator in aging. Axonal degeneration occurs in many 
neurodegenerative diseases. Sasaki et al. (2006) found that NAMPT can delay axon 
degeneration in the presence of nicotinamide in an in vitro Wallerian degeneration assay. 
These results suggest that increased activity of the NAD biosynthetic pathway stemming 
from nicotinamide promotes axonal protection. Van der Veer et al. (2007) reported that 
NAMPT can extend the lifespan of human smooth muscle cells. They found that replicative 
senescence of smooth muscle cells was preceded by a marked decline in the expression and 
activity of NAMPT. Furthermore, reducing NAMPT activity with the antagonist FK866 
induced premature senescence in smooth muscle cells. NAMPT overexpression also 
reduced the fraction of p53 that was acetylated on lysine 382, a target of SIRT1, suppressed 
an age-related increase in p53 expression, and increased the rate of p53 degradation. 
Moreover, add-back of p53 with recombinant adenovirus blocked the anti-aging effects of 
NAMPT (van der Veer et al., 2007). These data indicate that NAMPT is a longevity protein 
that can add stress-resistant life to human smooth muscle cells by optimizing SIRT1-
mediated p53 degradation. Recently, Benigi et al. (2009) noticed that the longevity 
phenotype in angiotension II type 1 receptor knockout mice was associated with an 
increased number of mitochondria and up-regulation of the prosurvival genes NAMPT and 
sirtuin 3 (Sirt3) in the kidney. They postulated that disruption of angiotension II type 1 
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receptor promotes longevity in mice, possibly through the attenuation of oxidative stress 
and overexpression of prosurvival genes such as NAMPT and Sirt 3. 
3.3 Atherosclerosis  
Atherosclerosis is a disease affecting arterial blood vessels. In a microarray experiment, 
Dahl et al. (2007) identified that NAMPT expression was markedly enhanced in carotid 
plaques from symptomatic individuals compared with plaques from asymptomatic 
individuals. Zhong et al. (2008) also reported that serum NAMPT was increased in 
patients with carotid plaques. Cheng et al. (2008) noticed that NAMPT levels in epicardial 
and abdominal adipose tissues were significantly higher in coronary artery disease (CAD) 
patients relative to control subjects. In addition, significantly higher tissue NAMPT levels 
from abdominal fat depots were found compared to those from epicardial fat in CAD 
patients. These findings suggest that abdominal adiposity may play a more significant 
role than epicardial fat in the pathogenesis of coronary atherosclerosis. More studies are 
warranted to firmly establish the relationship between NAMPT and atherosclerosis and to 
elucidate the role(s) and molecular mechanisms of NAMPT in the pathogenesis of 
atherosclerosis. 
3.4 Cancer 
Molecular screening, epidemiological survey and pharmacological studies have indicated 
that NAMPT may be an attractive diagnostic and drug target for cancer therapy. Hufton et 
al. (1999) first noticed that NAMPT expression was increased 6 fold in primary colorectal 
cancer over the normal control using the suppression subtractive cDNA hybridization 
technique. This result was confirmed at the protein and tissue levels by both western 
blotting and immunohistochemical analyses (Van Beijnum et al., 2002). Using cDNA 
microarray based expression profiling of different grades of astrocytomas, Reddy et al. 
(2008) identified several fold increased levels of NAMPT transcripts and protein in 
glioblastoma samples, suggesting that NAMPT could be a potential malignant astrocytoma 
serum marker and prognostic indicator in glioblastoma. 
Through a chemical screen to find new antitumor drugs, Hasmann and Schemainda (2003) 
identified the first low molecular weight compound, designated FK866 {the chemical 
name: (E)-N-[4-(1-benzoylpiperidin-4-yl) butyl]-3-(pyridin-3-yl) acrylamide}, which 
induced apoptosis by highly specific and potent inhibition of nicotinamide 
phosphoribosyltransferase in HepG2 human liver carcinoma cells. Using 1H-decoupled 
phosphorus (31P) magnetic resonance spectroscopy, Muruganandham et al. (2005) 
observed that FK866 (also known as APO866) increased apoptosis and subsequent 
radiation sensitivity in the mammary carcinoma. FK866 has been shown to have anti-
tumor, anti-metastatic and antiangiogenic activities in a murine renal cell carcinoma 
model (Drevs et al., 2003). The three dimensional structural analysis of the NAMPT–
FK866 complex by three groups revealed that the FK866 compound binds at the 
nicotinamide-binding site of NAMPT to competitively compete directly with the 
nicotinamide substrate to inhibit its activity (Khan et al., 2006; Kim, M.K. et al., 2006; 
Wang et al., 2006). These structural analyses provided a molecular basis for the inhibition 
of FK866 on NAMPT and a starting point for the development of new anticancer agents.  
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Accumulated evidence indicates that at least three molecular mechanisms may implicate 
NAMPT in the pathogenesis of cancer. First, NAMPT inhibits apoptosis of tumor cells via its 
role as a key enzyme in NAD biosynthetic salvage pathway. Second, Li Y. et al. (2008) 
reported that NAMPT could activate an IL-6/STAT3 survival signaling pathway via a non-
enzymatic mechanism. Third, increased NAMPT activity has been associated with 
angiogenesis and neovascularization. Kim et al. (2008) found that NAMPT potently 
stimulates in vivo neovascularization in chick chorioallantoic membranes and in implanted 
mouse Matrigel plugs. Furthermore, Bae et al. (2009) reported that NAMPT-induced 
angiogenesis is mediated by endothelial fibroblast growth factor-2 (FGF-2). Therefore, 
inhibition of NAMPT activity provides a important anticancer target, since 
neovascularization by angiogenesis is the prerequisite for tumor growth and expansion 
(Chamberlain, 2008). 
3.5 Diabetes mellitus 
Diabetes mellitus, simply referred to as diabetes, is a syndrome of disordered metabolism with 
hyperglycemia as a hallmark phenotype. Its long and extensively-sought hereditary and 
environmental causes are not fully known. Initial attention brought to the relationship 
between NAMPT and Type 2 diabetes was due to the work by Fukuhara et al. (2005). They 
found that NAMPT is a secreted factor produced abundantly by visceral fat. Plasma NAMPT 
levels in NAMPT gene heterozygous knockout mice were only 2/3 of those in wild type mice 
but their plasma glucose level were significantly higher. This suggests that like insulin, 
NAMPT may have a physiological role in lowering plasma glucose levels. The authors found 
that NAMPT bound to the insulin receptor (IR) but not to the same site to which insulin binds. 
Similar to insulin, NAMPT could stimulate insulin signaling, such as inducing tyrosine 
phosphorylation of the IR, insulin receptor substrate–1 (IRS-1), and IRS-2 in the liver. Taken 
together, the authors considered NAMPT as an insulin-mimetic and dubbed it as visfatin. 
Although this paper was withdrawn from Science due to the variation of different batches of 
recombinant NAMPT for their adipogenic and insulin-mimetic activities (Fukuhara et al., 
2007), this report has immediately and continuously drawn increased interest among 
biomedical researchers to the roles and mechanisms underpinning NAMPT in the 
pathogenesis of diabetes, obesity, insulin resistance, and metabolic syndrome. 
The epidemiological survey of the relationship between NAMPT and Type 2 diabetes by 
Fukuhara et al. (2005) has been supported by a number of subsequent studies which 
reported that the level of plasma NAMPT and/or the amount of visceral fat NAMPT mRNA 
were increased significantly in or positively associated with Type 2 diabetes or obesity or 
insulin resistance or metabolic syndrome in patients under the baseline without any 
intervention of medication, surgery, and other reagents (Berndt et al., 2005; Chen et al., 
2006; Krzyzanowska et al., 2006; Dogru et al., 2007; Fernandez-Real et al., 2007; 
Lewandowski et al., 2007; Sandeep et al., 2007; Alghasham & Barakat, 2008; Botella-
Carretero et al., 2008; Liang et al., 2008; Mazaki-Tovi et al., 2008; Retnakaran et al., 2008; 
Ziegelmeier et al., 2008; Hallschmid et al., 2009). Patients with Type 1 diabetes also had 
higher NAMPT concentrations than controls (Haider et al., 2006; Lopez-Bermejo et al., 
2006). However, other groups have obtained opposite findings (Jian et al., 2006; Akturk et 
al., 2008; Kato et al., 2009) or no changes of plasma NAMPT level in Type 2 diabetes (Chan 
et al., 2006; Pagano et al., 2006; Takebayashi et al., 2007; Tsiotra et al., 2007; Palin et al., 
2008). These conflicting findings on the correlation of plasma NAMPT level with diabetes 
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may stem from four major reasons: small sample sizes, variable phenotyping criteria, 
different populations and ethnicities and assay variation. The biological role and molecular 
mechanism of NAMPT related to diabetes remains to be fully elucidated.  
3.6 Rheumatoid arthritis 
Rheumatoid arthritis [RA] is a chronic, systemic autoimmune disorder that most commonly 
causes inflammation and tissue damage in joints. Despite that the first recognized description 
of rheumatoid arthritis was made in 1800 by Dr. Augustin Jacob Landré-Beauvais in Paris 
(Landre-Beauvais, 2001), its pathogenesis remains incompletely understood. Otero et al. (2006) 
first reported that patients with rheumatoid arthritis showed higher plasma levels of NAMPT, 
leptin, and adiponectin than healthy controls. These findings were confirmed by Nowell et al. 
(2006), Bretano et al. (2007) and Matsui et al. (2008). When compared with osteoarthritis (OA) 
patients, Nowell and colleagues detected elevated levels of NAMPT in synovial fluid from RA 
patients (Nowell et al., 2006).  In a large survey of 167 RA patients and 91 control subjects, Rho 
et al. (2009) found that elevated levels of NAMPT correlated with both radiological joint 
destruction and mediators of inflammation.  
NAMPT is a pleiotropic protein which can induce the expression of a number of genes (e.g. 
CCR2, CCR3, Cox-2, IL-6, IL-8, IL-16, ICAM1, MCP-1, MMP-2, MMP-9, VCAM1, VEGF) 
(Ognjanovic et al., 2001; Kim, S.R. et al., 2007; Adya et al., 2008; Adya et al., 2008; Kim, S.R. 
et al., 2008; Li, H. et al., 2008; Adya et al., 2009; Liu, P. et al., 2009; Liu, S.W. et al., 2009). It is 
suggested that NAMPT affects the innate immune system’s inflammatory response in the 
pathogenesis of rheumatoid arthritis via regulating expression of those inflammatory 
cytokines or activators. However, the mechanism by which NAMPT mediates the cytokine 
signaling cascade has not yet been determined fully. 
3.7 Sepsis 
Sepsis, a life-threatening disorder characterized by a whole-body inflammatory state caused 
by infection, is a frequent cause of ALI/ARDS. Jia et al. (2004) reported that NAMPT 
functions as a novel inflammatory cytokine that plays a requisite role in the delayed 
neutrophil apoptosis of clinical and experimental sepsis. They found that transcription of 
the NAMPT gene is increased in neutrophils from septic patients, while the prevention of 
NAMPT translation through the use of an antisense oligonucleotide largely restored the 
normal kinetics of apoptosis. Moreover, the incubation of quiescent neutrophils from 
healthy volunteers with recombinant NAMPT results in dose-dependent inhibition of 
apoptosis, while antisense NAMPT prevents the inhibition of apoptosis that results from 
exposure to lipopolysaccharide (LPS) or to a variety of host-derived inflammatory cytokines 
(Jia et al., 2004). The authors postulate that the prolonged survival of activated neutrophils 
may be linked to sustained inflammation and the organ injury of sepsis. 
Because of its multiple functional roles in physiology, the list of NAMPT involvement in 
various human diseases is expected to grow.  
4. NAMPT inhibitors 
As summarized in the first part of this chapter, NAMPT is considered as a rate-limiting 
enzyme of a mammalian synthetic pathway of NAD synthesis. Thus, NAMPT may exert its 
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physiological and pathological roles by regulating the synthesis of NAD. NAD plays a 
major role in the regulation of several essential cellular processes. It’s an essential coenzyme 
in metabolic pathways, and important in several biological processes including signal 
transduction (Corda & Di Girolamo, 2003), DNA repair (Menissier de Murcia et al., 2003), 
calcium homeostasis (Lee, H.C., 2001), gene regulation (Blander & Guarente, 2004), 
longevity (Lin et al., 2000), genomic integrity (Schreiber et al., 2006) and apoptosis (Wright 
et al., 1996). Additionally, as reviewed above, NAMPT is a pleiotropic protein which also 
functions via non-enzymatic mechanisms. Thus, NAMPT has become an attractive target in 
the treatment of many diseases. This section will focus on the development and progress of 
various NAMPT inhibitors and their applications.  
4.1 Chemical inhibitors of NAMPT 
4.1.1 FK866 
The first NAMPT inhibitor, FK866 (also called APO866 or WK175, (E)-N-[4-(1-
benzoylpiperidin-4-yl) butyl] acrylamide-3-(pyridin-3-yl), was reported by Hasmann and 
Schemainda, who found that FK866 induced apoptosis by a highly specific and potent 
inhibition of nicotinamide phosphoribosyltransferase in HepG2 human liver carcinoma 
cells (Hasmann & Schemainda, 2003). FK866 has no primary effect on cellular energy 
metabolism and thus has no direct and immediate cytotoxicity, but rather gradually 
depletes the cells of a vital factor, NAD, by inhibiting NAMPT, which eventually triggers 
apoptosis. The authors proposed that FK866 may be used for treatment of diseases 
involving deregulated apoptosis, such as cancer, or as a sensitizer for genotoxic agents. 
Furthermore, FK866 may provide an important tool for investigation of the molecular 
triggers of the mitochondrial pathway leading to apoptosis through enabling temporal 
separation of decreased NAD levels from ATP breakdown and apoptosis (Hasmann & 
Schemainda, 2003; Pittelli et al., 2010). 
Depletion of cellular NAD levels leads to lowered ATP levels and the inhibition of poly 
(ADP-ribose) polymerases (PARPs) (Khan et al., 2007). Cancer cells have a high demand of 
both PARP and ATP, and they also display higher energy requirements (Hufton et al., 
1999). Thus, cancer cells would be expected to be more sensitive than normal cells to the 
inhibition of NAD synthesis (Hasmann & Schemainda, 2003; Billington et al., 2008; 
Nahimana et al., 2009). Therefore, since NAMPT acts as a key enzyme of NAD synthesis, its 
inhibitors could provide an effective cancer therapy. Additional reports have demonstrated 
that FK866 elicited massive cell death in primary leukemia cells and in numerous 
leukemia/lymphoma cell lines (Nahimana et al., 2009; Zoppoli et al., 2010). FK866 has been 
shown to have anti-tumor, anti-metastatic and antiangiogenic activities in a murine renal 
cell carcinoma model. Nahimana et al. (2009) investigated the cytotoxic effects of FK866 in 
both in vitro and in vivo assays, using a cell panel of human hematologic malignancies and 
early and established human hematologic cancers, respectively. They observed in in vitro 
assays that FK866-induced apoptosis involved an initial decrease in intracellular NAD levels 
that were subsequently accompanied by decreases in intracellular ATP levels. In animal 
models of human acute myeloid leukemia, lymphoblastic lymphoma, and leukemia, FK866 
as a single agent prevented and abrogated tumor growth without significant toxicity to the 
animals. These findings demonstrated that FK866 displayed strong anticancer activity in 
hematologic malignancies both in vitro and in vivo.  
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FK866 was also found to improve the sensitivity of other anticancer agents. The main 
objectives of combination chemotherapy are an increased response rate against the tumor 
and minimization of adverse effects of drugs without compromising efficacy of treatment. 
Using1H-decoupled phosphorus (31P) magnetic resonance spectroscopy, Muruganandham 
et al. (2005) observed that FK866 increased cell death (apoptosis) and subsequent 
radiation sensitivity in the mammary carcinoma. Pogrebniak et al. (2006) treated THP-1 
and K562 cells with FK866 and various cytotoxic agents: the antimetabolite Ara-C, the 
DNA-intercalating agent daunorubicin and the alkylating compounds 1-methyl-3-nitro-1-
nitrosoguanidinium (MNNG) and melphalan. The results showed the anticancer activity 
of FK866 was particularly obvious in combination with substances like MNNG that cause 
NAD depletion chemo-sensitizing. Additionally, Yang et al. (2010) combined FK866 and 
the indoleamine 2,3-dioxygenase inhibitor L-1-methyl-tryptophan (L-1MT) in the 
treatment of mouse tumor models. The combination of FK866 and L-1MT had a better 
therapeutic effect than did either L-1MT or FK866 alone. 
 
Fig. 1. Representative ribbon diagram of two FK-866 molecules binding to the NAMPT 
dimer. The two FK-866 molecules are shown in red. The two monomers are shown in slate 
and green (subunit A) and pale blue and green (subunit B), respectively. This figure is 
copied from Kim M.K. et al (2006) with permission from Elsevier. 
The mechanism of FK866 inhibition of NAMPT has been well characterized. Three 
dimensional structural analyses of the NAMPT–FK866 complex revealed that FK866 binds 
at the nicotinamide-binding site of NAMPT, thus functioning as a competitive inhibitor of 
NAMPT enzymatic activity (Khan et al., 2006; Kim, M.K. et al., 2006; Wang et al., 2006). A 
representative crystal structure of NAMPT-FK866 binding is shown in Figure 1 (Kim, M.K. 
et al., 2006). FK-866 binds to the active site of NAMPT with higher affinity than either the 
substrate or the product does. The benzoylpiperidin group of FK-866 plays a key role in 
binding to NAMPT in hydrophobic interactions (Kim, M.K. et al., 2006). These structural 
www.intechopen.com
 
Chemical Biology 50
analyses provided a molecular basis for the inhibition of FK866 on NAMPT and a starting 
point for the development of new anticancer agents. 
The first human study of FK866 in the treatment of cancer was reported by Holen et al. 
(2008). They collected serial plasma and blood samples from 24 patients, with advanced 
solid tumors, treated with increasing doses of FK866. The patient age ranged from 34-78 and 
the dose of FK866 ranged from 0.144 mg/m2/h to 0.018mg/m2/h. The recommended dose 
for phase II clinical trial was 0.126mg/m2/h, which was given as a continuous 96 h infusion 
every 28 days. Thrombocytopenia was the main toxicity of FK866. Plasma analysis showed 
that FK866 did not affect VEGF concentration. FK866 has been used in phase II and I/II 
clinical trials against cancer, including advanced melanoma, cutaneous T-cell lymphoma 
and B-chronic lymphocytic leukemia (Holen et al., 2008; Olesen et al., 2010a, 2010b).  
FK866 has also been applied to treat a mouse model of collagen induced arthritis (CIA). 
Busso et al. (2008) carried out a CIA curative experiment using the optimal dose of FK866.  
Twenty mice with CIA were treated twice daily with 10 mg/kg/ip of FK866 from the first 
day onward of appearance of clinical arthritis for 14 consecutive days. They found that 
FK866 effectively reduced arthritis severity with comparable activity to etanercept, and 
decreased proinflammatory cytokine secretion in affected joints. Paws from FK866-treated 
mice showed minimal signs of inflammation after 2 weeks of treatment whereas paws from 
placebo-treated mice were still inflamed (Figure 2). This study indicates that the inhibition 
of NAMPT might have therapeutic efficacy in immune-mediated inflammatory disorders. 
 
FK866                 Placebo 
Fig. 2. FK866 treatment alleviated inflammation in a CIA mouse model. Collagen induced 
arthritis was initiated in male DBA/1 mice. Mice were treated for 14 consecutive days with 
two injections of 10 mg/kg/IP/day of APO866 from the first day onward of appearance of 
clinical arthritis (clinical score >1, mild swelling and/or erythema). Placebo mice received 
vehicle only. One of parameters to evaluate the FK866 therapeutic effect on arthritis is 
presented here with paws of FK866-treated (left) showing diminished swelling and 
inflammation compared to those in placebo-treated (right) arthritic mouse. This figure was 
copied from Busso et al. (2008). 
4.1.2 CHS 828 
CHS 828 (N-(6-chlorophenoxyhexyl)-NĻ-cyano-Nļ-4-pyridylguanidine, GMX1778, active 
form of GMN1777), a cyanoguanidine compound, which displayed promising preclinical 
anticancer activity, is another important NAMPT inhibitor currently in phase II clinical 
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trials in oncology (Schoua C., 1997; Hjarnaa et al., 1999; Olesen et al., 2010b; von 
Heideman et al., 2010). Hjarnaa et al. (1999) first demonstrated the anticancer properties 
of CHS 828 both in vitro and in vivo using established cancer cell lines and in rodent 
models of tumor growth, respectively. The mechanism of this small molecular inhibitor 
has been hypothesized to function through NF-κB inhibition (Schoua C., 1997; Hassan et 
al., 2006), but the exact mechanism was undefined. Olesen et al. (2004) originally found no 
common resistance mechanism between CHS 828 resistant human small cell lung 
carcinoma NYH cells (NYH/CHS) and NF-κB inhibitors resistant NYH cells. For FK866, it 
was observed that its cross-resistance was comparable to CHS 828 in NYH/CHS cells. 
CHS 828 was subsequently defined as an inhibitor of NAD synthesis as increasing cellular 
levels of NAD were able to completely block cytotoxicity of CHS 828, which is similar to 
FK866. Furthermore, crystal structure and in vitro biochemistry results showed that 
FK866 and CHS 828 shared a binding site in the active site of NAMPT (Kim, M.K. et al., 
2006; Olesen et al., 2008, 2010a). Thus, CHS 828 is conclusively identified as a competitive 
inhibitor of NAMPT.  
4.1.3 Other chemical inhibitors 
Kang et al. (2009) designed and synthesized IS001, in which a ribose ring was added to the 
FK866 pyridyl ring. The ribose ring of IS001 did not improve its solubility and binding 
interactions. The structures of the NAMPT-IS001 and NAMPT-FK866 complexes are nearly 
identical. You et al. (2011) replaced the pyridine ring of FK866 with various heteroaromatic 
rings for combination with a simple ribose-mimicking moiety containing a diol group. One 
analogue, compound 7, showed superior anti-cancer activity to FK866 (IC50 > 20μM) in 
human leukemia cells (K562) with an IC50 value of 1.4μM, but not in other cancer cell lines. 
Crystal structure of NAMPT-compound 7 demonstrated the binding site of compound 7 
was nearly identical to that of FK866 and NMN. 
TP201565, a potent analogue of CHS 828, displayed inhibition activity in xenograft models 
(Hjarnaa et al., 1999). TP201565 shows more than 10 fold increased activity in sensitive 
cancer cell lines compared to FK866 and CHS 828. Additionally, computer modeling 
analysis predicted that TP201565 inhibits NAMPT by binding to the same site as FK866 and 
CHS 828. Myriad Pharmaceuticals (http://www.myrexis.com) is developing a series of 
NAMPT inhibitors, such as MPC-9528, CB30865, MPI0479883. These inhibitors, which are 
designed analogues of FK866 and CHS 828, potently inhibited NAMPT activity and cancer 
cell growth with lower IC50 values than previously reported inhibitors. 
4.2 NAMPT siRNA/shRNA   
RNA interference (RNAi) is a natural biological mechanism where gene expression is 
silenced in a highly specific manner through the addition of double stranded RNA (dsRNA). 
Once dsRNA enters the cell, it is cleaved by an RNase III –like enzyme, Dicer, into double 
stranded small interfering RNAs (siRNA). The resulting siRNA with 21-23 nucleotides in 
length, containing 2 nucleotide overhangs on the 3’ ends, integrate into a multi-subunit 
protein complex, RNAi induced silencing complex (RISC). The RISC-bound antisense strand 
then serves as a guide for targeting the activated complex to complementary mRNA 
sequences, resulting in subsequent mRNA cleavage and degradation. Small hairpin RNA or 
short hairpin RNA (shRNA) is a sequence of RNA that makes a tight hairpin turn that can 
be used for RNA interference. shRNA uses a vector introduced into cells and utilizes the U6 
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or H1 promoter to ensure that the shRNA is constitutively expressed. This vector is usually 
passed on to daughter cells, allowing the gene silencing to be inherited. The shRNA hairpin 
structure is cleaved into siRNA, which is then bound to the RISC. This complex binds to and 
cleaves target mRNAs which match the siRNA that is bound to it. Knock down of gene 
expression by siRNA and shRNA technology has become a popular and effective tool to 
dissect gene function in the current functional genomics era. 
Ye et al. (2005b) employed NAMPT stealth siRNAs to explore the pathophysiological 
relevance of the altered NAMPT expression to the lung endothelial barrier dysregulation 
induced by thrombin and the pathogenesis of ALI. Acute lung injury (ALI) is characterized 
by a diffuse intense inflammatory process and by damage to both endothelial and epithelial 
cell barriers. The NAMPT gene was highly expressed in ALI and our group reported that 
NAMPT was a biomarker in ALI (Ye et al., 2005a). We studied whether downregulation of 
NAMPT protein expression by the NAMPT-specific siRNA would affect thrombin-induced 
decreases in human lung endothelial cell barrier function (Ye et al., 2005b). The results 
revealed that NAMPT expression was decreased significantly and the thrombin effect on 
cell barrier function was attenuated by NAMPT siRNA treatment in cultured human 
pulmonary artery endothelial cells (HPAEC), while siRNA had no effect on the protein 
expression level of ǃ-actin, a house-keeping gene. Similar results were also obtained in A549 
cells, a lung alveolar type II epithelial cell line.  
NAMPT levels in serum and synovial fluid are elevated in RA patients. RA synovial 
fibroblasts (RASFs) were major NAMPT expressing cells. Brentano et al. (2007) used siRNA 
to silence NAMPT expression in RASF, which significantly inhibited basal and TLR ligand-
induced production of IL-6, IL-8, MMP-1, and MMP-3. Van der Veer et al (2005) knocked 
down endogenous NAMPT in smooth muscle cells (SMC) to explore if the conversion of the 
SMC phenotype from a proliferative state to a nonproliferative state was accompanied by 
up-regulation of NAMPT. This shift of SMC phenotype is essential for conferring vasomotor 
function to developing and remodeling blood vessels. SMC, transfected with NAMPT 
siRNA, exhibited significant decrease in NAMPT mRNA and protein. Furthermore, they 
found that NAMPT siRNA treatment increased SMC apoptosis and reduced the capacity of 
synthetic SMCs to mature to a contractile state. NAMPT expression also increased during 
macrophage differentiation. To examine the role of NAMPT in macrophages differentiation, 
NAMPT siRNA was transfected into macrophages to silence NAMPT. Dahl et al. (2007) 
found that silencing of NAMPT increased lipid accumulation in THP-1 macrophages, 
increased ADRP (adipose differentiation-related protein) and cholesterol levels in oxidized 
LDL stimulated macrophages, and enhanced the binding of acetylated LDL in these cells. 
Cumulatively, these results indicate that NAMPT siRNAs could effectively and specifically 
inhibit the NAMPT expression and its function, which may be exploited as a promising 
strategy for NAMPT expression based therapy in relevant human diseases. 
Sigma Company (http://www.sigmaaldrich.com/) now markets MISSION® NAMPT 
esiRNA. MISSION esiRNAs are endoribonuclease-prepared siRNA pools comprised of a 
heterogeneous mixture of siRNAs that all target the same mRNA sequence. These 
multiple silencing triggers lead to highly specific and effective gene silencing with lower 
off-target effects than single or pooled siRNAs. Although no experimental report on the 
true effectiveness of MISSION® NAMPT esiRNA to silence the NAMPT expression 
appears in the literature yet, MISSION® NAMPT esiRNA may gain steam over other 
NAMPT siRNA tools soon. 
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4.3 Antisense oligonucleotide to NAMPT 
An antisense oligonucleotide is a synthesized strand of nucleic acid which binds to and 
inactivates its corresponding mRNA molecule effectively making the target gene silent. 
Generally, they are relatively short (13–25 nucleotides) and hybridize (at least in theory) to a 
unique sequence of target present in cells.  
Jia et al. (2004) used a phosphorothioate-modified antisense oligonucleotide to block 
NAMPT mRNA expression in neutrophils. Neutrophils play an important role in sepsis. 
Activated neutrophils have been implicated in the increased micro vascular permeability of 
systemic inflammation (Gautam et al., 2001) and in the pathogenesis of inflammatory injury 
to the lung (Lee, W.L. & Downey, 2001), liver (Ho et al., 1996), gastrointestinal tract (Kubes 
et al., 1992), and kidney (Lauriat & Linas, 1998). The number and activity of neutrophils are 
tightly linked to infection and inflammatory injury, and regulated by apoptotic program. 
LPS and other inflammatory cytokines can inhibit neutrophil apoptosis. The research by Jia 
et al. demonstrated that NAMPT is synthesized and released by neutrophils in response to 
inflammatory stimuli and that it plays a requisite role in the inhibition of apoptosis in 
neutrophils (Jia et al., 2004). The NAMPT antisense oligonucleotide prevented neutrophil 
apoptosis induced by either LPS or other inflammatory cytokines. In neutrophils of patients 
with sepsis, addition of NAMPT antisense oligonucleotide resulted in a greater than two 
fold increase in rates of apoptosis. This study demonstrated that the antisense 
oligonucleotide to NAMPT could effectively inhibit NAMPT expression, which could prove 
useful as a new therapeutic tool. 
4.4 NAMPT miRNA 
MicroRNAs (miRNAs), short ribonucleic acid (RNA) molecules, are post-transcriptional 
regulators, about 22 nucleotides long. miRNAs could bind to 3’ UTR of messenger RNA 
transcripts (mRNAs) resulting in translational repression and gene silencing. Gene silencing 
may occur either via mRNA degradation or preventing mRNA from being translated. It has 
been demonstrated that if there is complete complementation between the miRNA and 
target mRNA sequence, mRNA can be cleaved and degraded.  
Elangovan et al. (2011) reported at the American Thoracic Society Annual Conference, 2011 
that two miRNA hsa-miR-374a and hsa-miR-568 potentially bound to the 3’ UTR of NAMPT 
mRNA and thereby inhibited its expression. In human pulmonary artery endothelia cell 
(HPAEC) transfected with the luc-Nampt-3’UTR reporter construct and miRNAs, they 
found that hsa-miR-374a and hsa-miR-568 effectively reduced LPS- and cyclic stretch-
stimulated NAMPT expression in cultured HPAEC cell by both dual luciferase assay and 
immunoblotting. This study indicates that synthetic NAMPT miRNAs have potential to be a 
novel class of therapeutic molecules.  
Currently, several companies, such as Sigma (http://www.sigmaaldrich.com/) and 
Dharmacon (http://www.dharmacon.com/), offer the products of NAMPT miRNA 
mimics. MicroRNA mimics are double-stranded RNA oligonucleotides and are chemically 
modified. They effectively mimic endogenous mature miRNA functions with a superior 
performance in comparison to native double-stranded miRNA. Although there is yet a 
report about the application of NAMPT miRNA mimics, NAMPT miRNA mimics may 
gain an advantage over natural NAMPT miRNA as more effective inhibitors of NAMPT 
for the reasons as described above.  
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4.5 Antibody to NAMPT 
An antibody, also known as an immunoglobulin, is produced by the immune system to 
identify and neutralize a foreign object by recognizing its antigen, a unique part of the 
foreign target. The current progress in biotechnology and genetic engineering has kindled a 
growing interest in antibody based therapy, which has quickly become incorporated into the 
therapeutic armamentarium for various human diseases. It will be no exception for the 
development of NAMPT antibody based therapy.  
Our group has evaluated whether NAMPT antibody can block the function of NAMPT and 
thus attenuate ventilator induced lung injury (VILI) in a mouse model since NAMPT 
overexpression seemed to play a significant role in the pathogenesis of acute lung injury (Hong 
et al., 2008). We found that simultaneous instillation of rhNAMPT (20 mg/mouse) and NAMPT 
neutralizing antibody produced dramatic reductions in rhNAMPT-induced PMN recruitment. 
The intratracheal delivery of NAMPT neutralizing antibody (30 min before mechanical 
ventilation) abolished VILI-induced increases in total BAL cell counts and significantly 
decreased PMN influx into the alveolar space as well as VILI-mediated increases in lung tissue 
albumin. This result indicates that NAMPT antibody based strategy may be a viable therapeutic 
modality to acute lung injury. Although this was only one case report (Hong et al., 2008), it 
could ignite an increasing interest at NAMPT antibody based therapy to other diseases where a 
dysregulated overexpression of NAMPT gene is one of the key features.  
4.6 NAMPT gene knockout 
Gene knockout (KO), namely the inactivation of a specific gene within an organism, is a 
potential important gene therapy technique. In mouse experiments, typically, a gene target 
vector contains a selective marker in the center with both 5'- and 3'- arms, whose sequences 
are homologous to the targeted gene. This gene target vector is introduced into the mouse 
embryonic stem cell by electroporation. As the embryonic stem cell divides, the original 
gene segment is replaced through homologous recombination in a small number of the 
divided cells. After the target vector is integrated in the cognate position, the stem cells are 
then introduced into a female mouse. Subsequently, a knock-out mouse line would be 
engendered after further characterization. 
To explore the effect of NAMPT to ventilator-induced lung injury (VILI) in vivo, Hong et al. 
(2008) generated a heterozygous NAMPT+/- mouse line and subsequently exposed the mouse 
to a model of severe VILI. The results were opposite between the rhNAMPT and NAMPT+/- 
mice when exposed to a model of severe VILI. In rhNAMPT mice, it was observed that 
dramatic increases in bronchoalveolar lavage (BAL) leukocytes, BAL protein, and cytokine 
levels (IL-6, TNF-a, KC). In contrast, NAMPT+/- mice exhibited significantly decreased 
expression of VILI associated genes, inflammatory lung injury and lower peak aspiratory 
pressures compared with control mice. These results suggest that NAMPT is a critical effecter in 
the development of ventilator induced lung pathobiology and it shows a promise that reducing 
NAMPT gene expression could protect lungs from VILI in human patients down the road.   
5. Perspective 
NAMPT has drawn an ever-increasing attention in biomedical fields because of its 
presumed pleiotropic physiological functions and its dysregulation implicated in a number 
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of human diseases and conditions. As of Aug 15, 2011, 836 publications have appeared in 
PubMed when searched with key words: NAMPT or PBEF or visfatin. 
A growing interest has been to develop inhibitors of NAMPT as a potential new therapeutic 
strategy to several human diseases where the dysregulated overexpression of NAMPT is 
implicated in their pathogeneses. Although there have been several reported methods to 
effectively inhibit NAMPT activity, such as small molecular chemicals, siRNA, miRNA, 
antisense oligonucleotide, and gene knock out, further improvement of these inhibitors are 
warranted. These include improving the efficacy, reducing side effects and enhancing the 
specificity. For FK866, or other synthetic chemical inhibitors, the main obstacle to be 
overcome is toxicity. Enhancing the potency, lowering the effective dosage and reducing the 
side effects are necessary for the improvement of this NAMPT inhibitor class. Although 
RNA interference technology by siRNA and miRNA has become a standard research tool 
for genetic studies and a new class of drugs designed to silence disease-causing genes, it is 
still in the development stage. RNA in general is more unstable than DNA and tends to be 
degraded easily. siRNA or miRNA may also cause an immune response which causes the 
body to reject the foreign RNA. Transfection inefficiency is a problem both in treatment and 
in study of RNA interference. Off target effects are a major concern. The stability issue of 
antisense oligonucleotides in blood and tissue is still not satisfactorily resolved. Although 
our group demonstrated that antibody blocking of NAMPT could attenuate acute lung 
injury in a mouse model, antibody based inhibition of NAMPT is far from fully developed 
as a effective therapy to other diseases. Gene therapy still has a long way to go before 
clinical fruition. NAMPT aptamers or other forms of NAMPT inhibitors have yet come into 
the world. Nevertheless, it is anticipated that improved and new NAMPT inhibitors will be 
developed within next few years. NAMPT based strategy holds an immense promise in 
management of various human conditions. 
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